Baricitinib versus placebo or adalimumab in rheumatoid arthritis

<h4>Background</h4> <p>Baricitinib is an oral, reversible, JAK1/JAK2 inhibitor that may have therapeutic value in patients with rheumatoid arthritis.</p> <h4>Methods</h4> <p>In this 52-week, phase 3, double-blind, placebo and active-controlled study, 1307 p...

Description complète

Détails bibliographiques
Auteurs principaux:	Taylor, P, Keystone, E, Van der Heijde, D, Weinblatt, M, del Carmen Morales, L, Reyes Gonzaga, J, Yakushin, S, Ishii, T, Emoto, K, Beattie, S, Arora, V, Gaich, C, Rooney, T, Schlichting, D, Macias, W, de Bono, S, Tanaka, Y
Format:	Journal article
Publié:	Massachusetts Medical Society 2017

Baricitinib versus placebo or adalimumab in rheumatoid arthritis

Documents similaires